[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365017-105":59,"doc-detail-365017-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evaluation-of-circhipk3-biomarker-potential-in-breast-cancer-registered-report-stage-ii","Evaluation of CircHIPK3 biomarker potential in breast cancer - Registered Report Stage II","","Background: Investigation of circular RNAs (circRNAs) in cancers is growing rapidly. This study evaluated the circHIPK3 biomarker potential in breast cancer (BC) using tumor and reference cohorts. Methods: Analyses included 100 cancer and adjacent normal tissues, plasma from 95 cancer patients, 42 fibroadenomatosis patients, and 93 healthy donors; expression profiling used Illumina HiSeq 2000, and circHIPK3 validation used qRT-PCR. Diagnostic efficacy was assessed by ROC. Results: circHIPK3 showed highest expression in cancer tissues and was upregulated in BC tissues and plasma; AUC was 0.8087 with high specificity and sensitivity, and upregulation correlated with tumor size. Conclusions: circHIPK3 is significantly upregulated and demonstrates diagnostic potential in BC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluation-of-circhipk3-biomarker-potential-in-breast-cancer-registered-report-stage-ii/365017/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluation-of-circhipk3-biomarker-potential-in-breast-cancer-registered-report-stage-ii/365017.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the study evaluate about circHIPK3 in breast cancer?","Question",{"text":112,"@type":113},"It evaluates whether circHIPK3 can serve as a diagnostic biomarker for breast cancer, including its expression patterns in tissues and plasma and its diagnostic performance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were circHIPK3 expression levels measured?",{"text":117,"@type":113},"Expression profiling was performed using Illumina high-throughput HiSeq 2000 sequencing on paired cancerous and normal breast tissues, and expression confirmation used quantitative real-time fluorescent PCR (qRT-PCR) to detect circHIPK3 levels.",{"name":119,"@type":110,"acceptedAnswer":120},"What diagnostic performance did circHIPK3 show?",{"text":121,"@type":113},"Diagnostic potential was assessed by ROC, yielding an AUC of 0.8087 (95% CI: 0.7309 to 0.8866, P \u003C 0.0001), with high specificity and sensitivity, including comparisons alongside CA-15-3 and CEA.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365017,1790197483,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Practical Laboratory Medicine 45 (2025) e00470  \nContents lists available at ScienceDirect  \nPractical Laboratory Medicine  \njournal [homepage:](homepage: www.elsevier.com/locate/plabm)[ www.elsevier.com/locate/plabm](homepage: www.elsevier.com/locate/plabm)  \n| Registered Report Stage II\u003Cbr>Evaluation of CircHIPK3 biomarker potential in breast cancer\u003Cbr>Ensiyeh Bahadorana, Davood Mohammadib, Manijeh Jalilvanda, Sahar Moghbelinejada,*\u003Cbr>a Cellular and Molecular Research Centre, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran\u003Cbr>b Department of Surgery, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran |  |\n| --- | --- |\n| A R T I C L E I N F O\u003Cbr>Keywords: Breast cancer\u003Cbr>Circular RNA Biomarker Liquid biopsy | A B S T R A C T\u003Cbr>Background: Nowadays, the investigation of circular RNAs (circRNAs) in various cancers is of great interest. In this research, we evaluated circHIPK3 biomarker potential in breast cancer (BC). Methods: The studied samples were 100 cancer and adjacent normal tissues, plasma from 95 cancer patients, 42 patients with fibroadenomatosis, and 93 healthy donors. Illumina highthroughput Hi Seq 2000 sequencing performed expression profiling on 4 pairs of cancerous and normal breast tissues. For expression confirmation, Quantitative real-time fluorescent polymerase chain reaction (qRT-PCR) was used to detect the expression level of circHIPK3. CircHIPK3 diagnostic efficacy was evaluated by the receiver operating characteristic curve (ROC).\u003Cbr>Results: Based on high-throughput sequencing and bioinformatics results circHIPK3 had the highest expression in cancer tissues (P = 0.00034). Real-time results showed expression upregulation of circHIPK3 in BC tissues and plasma in comparison to healthy controls (P \u003C 0.0001). For diagnostic potential, the area under the curve (AUC) result was 0.8087 (95 % CI: 0.7309 to 0.8866, P \u003C 0.0001). Also, our results showed high specificity and sensitivity of circHIPK3 when evaluated alongside the CA-15-3 and CEA. Pathologic criteria evaluation showed that upregulation of circHIPK3 correlates with tumor size.\u003Cbr>Conclusions: CircHIPK3 is significantly upregulated in BC tissues and plasma compared to healthy controls, demonstrating high diagnostic potential with an AUC of 0.8087. The expression ofcircHIPK3 correlates with tumor size, indicating its relevance in the pathologic assessment of BC. |\n\n1. Introduction  \nBreast cancer (BC) presents a major global health challenge as it is the most frequently diagnosed cancer worldwide, with over 2.3 million new cases reported in 2020. It remains the leading cause of cancer-related death among women, with approximately 685,000 fatalities in the same year. More than half of these diagnoses and two-thirds of the deaths occurred in less-developed regions. Projections estimate that by 2040, annual BC cases will surpass 3 million [1,2]. Despite significant advances in treatment, the complexity and heterogeneity of the BC demand the continuous exploration of novel molecular mechanisms. Moreover, early diagnosis is critical for effective treatment and improved prognoses [3,4]. BC screening primarily uses imaging techniques and serum tumor markers;  \n* Corresponding author. Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences. P.O. Box: 34197-59811, Qazvin, Iran.  \nE-mail addresses: [bahadoran.ensiyeh@gmail.com](bahadoran.ensiyeh@gmail.com) (E. Bahadoran), [d.mohammadi@gmail.com](d.mohammadi@gmail.com) (D. Mohammadi), [rahamj7@yahoo.com](rahamj7@yahoo.com)  \n(M. Jalilvand), [smoghbelinejad@qums.ac.ir](smoghbelinejad@qums.ac.ir) (S. Moghbelinejad).  \n[https://doi.org/10.1016/j.plabm.2025.e00470](https://doi.org/10.1016/j.plabm.2025.e00470)  \nReceived 30 September 2024; Received in revised form 14 March 2025; Accepted 20 March 2025 Available online 20 March 2025  \n2352-5517/©","cbCaigegpGxZkMNv","https://ap.wps.com/l/cbCaigegpGxZkMNv","pdf",1283599,"English","# Introduction\n## CircRNAs and their relevance to cancer diagnosis\n## CircHIPK3 and the rationale for study\n# Materials and methods\n## Sample cohorts and clinical groups\n## Sequencing and expression validation\n## Diagnostic assessment using ROC\n# Results\n## Expression profiling and qRT-PCR confirmation\n## Diagnostic performance and biomarker comparison\n## Association with clinicopathologic features\n# Conclusions","[{\"question\":\"What does the study evaluate about circHIPK3 in breast cancer?\",\"answer\":\"It evaluates whether circHIPK3 can serve as a diagnostic biomarker for breast cancer, including its expression patterns in tissues and plasma and its diagnostic performance.\"},{\"question\":\"How were circHIPK3 expression levels measured?\",\"answer\":\"Expression profiling was performed using Illumina high-throughput HiSeq 2000 sequencing on paired cancerous and normal breast tissues, and expression confirmation used quantitative real-time fluorescent PCR (qRT-PCR) to detect circHIPK3 levels.\"},{\"question\":\"What diagnostic performance did circHIPK3 show?\",\"answer\":\"Diagnostic potential was assessed by ROC, yielding an AUC of 0.8087 (95% CI: 0.7309 to 0.8866, P \\u003c 0.0001), with high specificity and sensitivity, including comparisons alongside CA-15-3 and CEA.\"}]","Evaluation of CircHIPK3 biomarker potential in breast cancer - Registered Report Stage II | PDF",1790159711,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efe037d9b020b81c92df5de7c9a5d71c.webp",983,1341,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d046e067ef898370482d59bdc9f1db84.webp",982,1340,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11246af2dfab6274af6751f1bcbe277f.webp",981,1338,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf7d6da23f50c92c28960a9af1adcbcf.webp",980,1337]